Entrada Therapeutics, Inc. TRDA
We take great care to ensure that the data presented and summarized in this overview for Entrada Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TRDA
View all-
Baker Bros. Advisors LP New York, NY4.87MShares$33.9 Million0.52% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$30.7 Million27.61% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$30.5 Million57.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.74MShares$19.1 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X02.12MShares$14.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$11.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.58MShares$11 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA1.05MShares$7.34 Million0.0% of portfolio
-
Step Stone Group LP La Jolla, CA761KShares$5.31 Million19.98% of portfolio
-
Geode Capital Management, LLC Boston, MA589KShares$4.11 Million0.0% of portfolio
Latest Institutional Activity in TRDA
Top Purchases
Top Sells
About TRDA
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Insider Transactions at TRDA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2025
|
5 Am Ventures V, L.P. |
SELL
Open market or private sale
|
Indirect |
6,422
-0.58%
|
$44,954
$7.12 P/Share
|
|
Jul 01
2025
|
5 Am Ventures V, L.P. |
SELL
Open market or private sale
|
Direct |
18,578
-0.58%
|
$130,046
$7.12 P/Share
|
|
Jul 01
2025
|
Kush Parmar |
SELL
Open market or private sale
|
Indirect |
25,000
-0.58%
|
$175,000
$7.12 P/Share
|
|
Jun 30
2025
|
5 Am Ventures V, L.P. |
SELL
Open market or private sale
|
Indirect |
6,422
-0.58%
|
$38,532
$6.81 P/Share
|
|
Jun 30
2025
|
5 Am Ventures V, L.P. |
SELL
Open market or private sale
|
Direct |
18,578
-0.58%
|
$111,468
$6.81 P/Share
|
|
Jun 30
2025
|
Kush Parmar |
SELL
Open market or private sale
|
Indirect |
25,000
-0.58%
|
$150,000
$6.81 P/Share
|
|
Jun 27
2025
|
5 Am Ventures V, L.P. |
SELL
Open market or private sale
|
Indirect |
19,265
-1.7%
|
$115,590
$6.91 P/Share
|
|
Jun 27
2025
|
5 Am Ventures V, L.P. |
SELL
Open market or private sale
|
Direct |
55,735
-1.7%
|
$334,410
$6.91 P/Share
|
|
Jun 27
2025
|
Kush Parmar |
SELL
Open market or private sale
|
Indirect |
75,000
-1.7%
|
$450,000
$6.91 P/Share
|
|
Apr 03
2025
|
Kory James Wentworth Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,134
+8.45%
|
$22,268
$2.1 P/Share
|
|
Mar 17
2025
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,784
-1.6%
|
$17,840
$10.67 P/Share
|
|
Mar 03
2025
|
Kory James Wentworth Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,929
-4.24%
|
$54,219
$11.68 P/Share
|
|
Mar 03
2025
|
Dipal Doshi CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,566
-3.97%
|
$193,226
$11.68 P/Share
|
|
Mar 03
2025
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Payment of exercise price or tax liability
|
Direct |
6,138
-2.98%
|
$67,518
$11.68 P/Share
|
|
Mar 03
2025
|
Nathan J Dowden President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,144
-2.77%
|
$56,584
$11.68 P/Share
|
|
Mar 01
2025
|
Kory James Wentworth Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,400
+26.73%
|
-
|
|
Mar 01
2025
|
Dipal Doshi CEO |
BUY
Grant, award, or other acquisition
|
Direct |
116,200
+20.82%
|
-
|
|
Mar 01
2025
|
Natarajan Sethuraman President, Research & Develop. |
BUY
Grant, award, or other acquisition
|
Direct |
60,800
+22.81%
|
-
|
|
Mar 01
2025
|
Nathan J Dowden President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
60,800
+24.64%
|
-
|
|
Dec 11
2024
|
Mpm Bio Ventures 2014, L.P. |
SELL
Open market or private sale
|
Indirect |
21,787
-0.49%
|
$435,740
$20.23 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 280K shares |
|---|---|
| Exercise of conversion of derivative security | 43.1K shares |
| Payment of exercise price or tax liability | 47.8K shares |
|---|---|
| Open market or private sale | 435K shares |